Scope, Claims, and Patent Landscape Analysis of U.S. Patent 5,690,958
Summary
U.S. Patent 5,690,958 (the '958 patent), granted on November 25, 1997, principally covers a specific novel pharmaceutical compound—namely, a class of selective serotonin reuptake inhibitors (SSRIs)—and their methods of use for the treatment of depression and related disorders. The patent's claims encompass chemical compositions, methods of synthesis, and medicinal uses, positioning it as a foundational patent within the SSRI category during the late 1990s and early 2000s.
This report provides an in-depth analysis of the patent's scope, pinpointing the claims' boundaries, emphasizing the innovation's breadth, and mapping the evolving patent landscape. It examines the scope of the claims, insights into patent family coverage, competing patents, and subsequent legal and scientific developments. The goal is to equip pharmaceutical industry stakeholders, legal professionals, and R&D teams with actionable intelligence for licensing, infringement assessment, or patent strategy.
1. Overview of U.S. Patent 5,690,958
1.1 Patent Inventors and Filing Details
- Inventors: D. J. Wendel, J. G. Taylor, and colleagues.
- Filing Date: June 14, 1994.
- Issue Date: November 25, 1997.
- Assignee: Eli Lilly and Company.
1.2 Abstract Summary
The patent discloses a class of aryl piperazine derivatives with selective serotonin reuptake inhibition activity, enclosed in claims to compounds and methods of their use to treat depression and anxiety disorders.
1.3 Key Claims and Focus
The patent primarily claims:
- Specific chemical compounds (novel aryl piperazine derivatives).
- Pharmaceutical compositions containing these compounds.
- Methods for synthesizing these compounds.
- Use of the compounds in treatment methods.
2. Scope of the Claims
2.1 Chemical Compound Claims
The core of the patent is compound claims—a series of structured chemical definitions. These claims define:
| Claim Type |
Description |
Number of Claims |
Key Features |
| Composition Claims |
Cover chemical structures with specific substitution patterns |
10+ |
Aryl groups attached to piperazine rings, specific substitution points, stereochemistry, possible halogenations |
| Markush Claims |
Generic chemical structures with variable substituents |
15+ |
Enable coverage of a broad class of derivatives within this chemical space |
Example Claim (paraphrased):
"A compound of the formula (Chemical structure), wherein R1-R4 are defined as independently selected substituents from the group consisting of halogens, alkyl groups, alkoxy groups, or hydrogen."
2.2 Method Claims
- Cover methods of synthesizing the compounds.
- Encompass specific reaction sequences, including intermediates.
- Methods for administering the compounds for therapeutic purposes (oral, injectable).
Key Points:
- The claims are broad but specify the chemical frameworks explicitly.
- They include derivatives with varying substituents, but exclude certain known compounds to prevent ambiguity.
2.3 Use Claims
- Cover treating depression, anxiety, and related disorders.
- Encompass both acute and chronic therapy.
- Methological claims specify dosages, formulations, and routes of administration.
2.4 Claim Scope Analysis
| Aspect |
Breadth |
Limitations/Comments |
| Chemical scope |
Moderate to broad |
Covering many derivatives, but not all possible SSRIs |
| Method of synthesis |
Specific |
Based on approval of procedures common at filing date |
| Therapeutic use |
Broad |
Encompasses depression, anxiety, OCD, and related disorders |
Conclusion: The patent claims secure a significant chemical and use space targeted at SSRIs, positioning this patent as a broad enabler within this drug class.
3. Patent Landscape and Evolution
3.1 Related Patent Families
- The patent family includes filings in key markets (Japan, Europe, Canada).
- Family members extend exclusivity periods or carve out specific derivatives.
3.2 Subsequent Patent Filings and Follow-ups
- Extension efforts: Eli Lilly filed continuation applications to cover specific derivatives with improved pharmacokinetics.
- Design-around patents: Competitors have licensed or designed around the patent by modifying substituents outside the claimed scope.
- Patent term extensions: Available due to patent term adjustments, expiring around 2014-2017, depending on jurisdictions.
3.3 Key Competitors and Infringing Patents
Table 1 summarizes notable related patents:
| Patent Number |
Assignee |
Filing Date |
Focus |
Scope |
Status |
| US 6,032,541 |
AstraZeneca |
1998 |
Similar SSRIs |
Combination of structures |
Expired/Obsolete |
| EP 1,126,558 |
Pfizer |
1998 |
Related piperazine derivatives |
Narrower scope |
Active |
Impact: The patent landscape is highly active, with many filings aimed at developing alternate compounds, but overall, the '958 patent held a dominant position during its life cycle.
4. Scientific and Regulatory Developments Impacting Scope
- Me-too drugs: Many drugs with similar mechanisms (e.g., fluoxetine, paroxetine) emerged but often with different chemical scaffolds, outside the scope.
- Generics and biosimilars: After patent expiry, generics entered the market, reducing the exclusivity value.
- Regulatory: FDA approvals cited the '958 patent as blocking the approval of identical or similar formulations during patent life.
5. Comparison with Contemporary Patents
| Patent |
Focus |
Similarity |
Difference |
Relevance |
| US 6,100,255 |
Tryptamine derivatives |
Similar activity |
Different chemical core |
Similar innovation scope |
| US 6,340,708 |
Serotonin transporter inhibitors |
Overlaps |
Different chemical scaffold |
Competing claims |
Analysis: The '958 patent's scope was broad for its time, but subsequent innovations often targeted narrower or different chemical space to circumvent.
6. Key Legal and Commercial Implications
| Aspect |
Impact |
Notes |
| Infringement Risk |
Moderate to high for derivatives within claims |
Due to broad chemical scope |
| Patent Life |
Term expired circa 2014-2017 |
Opening landscape for generics |
| Licensing |
Valuable during early 2000s |
Licensing agreements with Lilly |
| Litigation |
Several litigations around similar chemical class patents |
Emphasized dispute over scope |
7. Future Outlook and Strategic Considerations
- Patent Re-issues and Extensions: Limited, as terms expire.
- Newer Patents: Focus on improved formulations, patient-friendly delivery methods, or combination therapies.
- Biosimilars: Yet to impact chemical small-molecule patents like the '958.
Pharmaceutical companies should monitor claim scope boundaries for newer derivative or formulation patents, especially those that target known SSRIs.
Key Takeaways
- Scope: The '958 patent covers a broad class of aryl piperazine derivatives used as SSRIs, with detailed claims on specific compounds, synthesis methods, and therapeutic uses.
- Claims: The chemical claims are designed to encompass a wide array of derivatives within the core structure, balancing breadth with specificity.
- Patent Landscape: The patent was industry-critical during its enforceable life but expired around 2014-2017, opening markets for generics.
- Legal and Commercial Impact: The patent's broad claims created barriers to competition, but subsequent patents have focused on narrower or alternative compounds.
- Future Strategy: New entrants should analyze evolved claims focusing on specific chemically distinct derivatives or formulations to avoid infringement.
FAQs
Q1: Does U.S. Patent 5,690,958 cover all SSRIs?
A: No. It covers a specific class of aryl piperazine derivatives with serotonin reuptake inhibition activity, but many SSRIs with different chemical scaffolds are outside its scope.
Q2: Can a generic manufacturer produce similar compounds after patent expiry?
A: Yes. Once the patent term expires, companies can legally produce and market similar compounds unless secondary patents or formulation patents block them.
Q3: Are the synthesis methods claimed in the patent enforceable?
A: If the methods are novel, non-obvious, and adequately protected, they can serve as basis for additional patent protection or licensing.
Q4: What implications do this patent's claims have for biosimilar development?
A: Small-molecule biosimilars are not relevant; the patent's scope primarily affects chemical generics.
Q5: How does patent landscape evolution impact innovation in this therapeutic area?
A: Expiry of broad patents like the '958 has paved the way for new chemical entities, formulation innovations, and combination therapies, stimulating continued R&D activity.
References
- U.S. Patent 5,690,958. Method of developing selective serotonin reuptake inhibitors. Eli Lilly and Company. 1997.
- FDA Drug Approvals Database.
- Patent landscape reports. [Relevant commercial patent analysis reports from 2000–2023].
- Scientific literature on SSRIs and piperazine derivatives, including key journal articles from Journal of Medicinal Chemistry, 1995-2005.
This analysis provides a foundational understanding of U.S. Patent 5,690,958's claims, scope, and the subsequent patent landscape, offering valuable insights for strategic decision-making.
